The level of Aß42 in the cerebrospinal fluid determines the onset of preclinical AD and is associated with a strong predictive marker of cognitive decline in normal subjects (14–17), whereas total-tau and phosphorylated-tau are late-onset markers of AD (18). The gene discussed is MAPT; the disease is Alzheimer disease.